FindTrial
Sign In

Phase II Study of Z-206 in Patients with Active Crohn's Disease

Phase II Study of Z-206 in Patients with Active Crohn's Disease

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221421
Enrollment
Unknown
Registered
2011-03-29
Start date
2011-03-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active Crohn's disease

Interventions

investigational material(s) Generic name etc : Z-206 INN of investigational material : Mesalazine Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for

Sponsors

Zeria Pharmaceutical Co., Ltd.
Lead Sponsor
Kyowa Hakko Kirin Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: CDAI score : 200 to less than 350 Patients in whom mucosal lesions are observed at the area between the terminal ileum and rectum outpatient

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026